Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11174055.1Aexternal-prioritypatent/EP2420497B1/en
Application filed by Celgene CorporationfiledCriticalCelgene Corporation
Publication of CY1117266T1publicationCriticalpatent/CY1117266T1/en
Εδώ παρέχονται 5-υποκατεστημένες ενώσεις κιναζολινόνης, και φαρμακευτικώς αποδεκτά άλατα, επιδιαλυτωμένα χημικά σωματίδια, ενώσεις εγκλεισμού, στερεοϊσομερή, και προφάρμακα αυτών. Αποκαλύπτονται μέθοδοι χρήσης, και φαρμακευτικές συνθέσεις αυτών των ενώσεων.Herein are provided 5-substituted quinazolinone compounds, and pharmaceutically acceptable salts, solvates, encapsulants, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
CY20161100201T2006-09-262016-03-08
5-Substituted Quinazolinone Derivatives as Anti-Cancer Agents
CY1117266T1
(en)
cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
Compounds derived from pyrrolidin-2-carboxamide, p53-mdm2 interaction inhibitors; pharmaceutical composition that includes them; and its use in the preparation of useful medicines for the treatment of cancer.